Limited Clinical Utility of HLA-Cw6 Genotyping for Outcome Prediction in Psoriasis Patients Under Ustekinumab Therapy: a Monocentric, Retrospective Analysis

Overview

Journal Psoriasis (Auckl)

Publisher Dove Medical Press

Date 2018 May 4

PMID 29721444

Citations 5

Authors

Florian Anzengruber

Adhideb Ghosh

Julia-Tatjana Maul

Mathias Drach

Alexander A Navarini

Affiliations

Soon will be listed here.

Abstract

Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions.

Patients And Methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study.

Results: There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index.

Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6- patients.

Citing Articles

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.

Berna-Rico E, Perez-Bootello J, Abbad-Jaime de Aragon C, Gonzalez-Cantero A Int J Mol Sci. 2023; 24(12).

PMID: 37372997 PMC: 10298473. DOI: 10.3390/ijms24129850.

Towards Personalized Medicine in Psoriasis: Current Progress.

Camela E, Potestio L, Ruggiero A, Ocampo-Garza S, Fabbrocini G, Megna M Psoriasis (Auckl). 2022; 12:231-250.

PMID: 36071793 PMC: 9444142. DOI: 10.2147/PTT.S328460.

Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.

Talamonti M, Galluzzo M Ann Transl Med. 2020; 8(15):971.

PMID: 32953771 PMC: 7475382. DOI: 10.21037/atm.2020.04.05.

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.

van Vugt L, van den Reek J, Hannink G, Coenen M, de Jong E JAMA Dermatol. 2019; 155(6):708-715.

PMID: 30994858 PMC: 6563550. DOI: 10.1001/jamadermatol.2019.0098.

Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients.

Zalzala H, Abdullah G, Abbas M, Mohammedsalih H, Mahdi B Saudi Med J. 2018; 39(9):886-890.

PMID: 30251731 PMC: 6201012. DOI: 10.15537/smj.2018.9.23156.

References

ORielly D, Rahman P . Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2014; 28(5):673-85. DOI: 10.1016/j.berh.2014.10.010. View

Galluzzo M, Boca A, Botti E, Potenza C, Malara G, Malagoli P . IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis. Dermatology. 2015; 232(2):230-6. DOI: 10.1159/000441719. View

Gupta R, Debbaneh M, Liao W . Genetic Epidemiology of Psoriasis. Curr Dermatol Rep. 2015; 3(1):61-78. PMC: 4285384. DOI: 10.1007/s13671-013-0066-6. View

Stuart P, Nair R, Hiremagalore R, Kullavanijaya P, Tejasvi T, Lim H . Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1. Tissue Antigens. 2010; 76(5):387-97. PMC: 2970686. DOI: 10.1111/j.1399-0039.2010.01526.x. View

Sokolik R, Gebura K, Iwaszko M, Swierkot J, Korman L, Wiland P . Significance of association of HLA-C and HLA-E with psoriatic arthritis. Hum Immunol. 2014; 75(12):1188-91. DOI: 10.1016/j.humimm.2014.10.005. View

Li K, Huang C, Randazzo B, Li S, Szapary P, Curran M . HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program. J Invest Dermatol. 2016; 136(12):2364-2371. DOI: 10.1016/j.jid.2016.06.631. View

Chiu H, Wang T, Chan C, Cheng Y, Lin S, Tsai T . Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014; 171(5):1181-8. DOI: 10.1111/bjd.13056. View

Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M . Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013; 169(2):458-63. DOI: 10.1111/bjd.12331. View

Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan P, Thappa D, Negi V . Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol. 2017; 73(8):965-971. DOI: 10.1007/s00228-017-2255-x. View

10.

Nair R, Stuart P, Henseler T, Jenisch S, Chia N, Westphal E . Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet. 2000; 66(6):1833-44. PMC: 1378062. DOI: 10.1086/302932. View

11.

Burlando M, Cozzani E, Campisi C, Di Costanzo A, Parodi A . Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis. Acta Derm Venereol. 2015; 96(6):858-9. DOI: 10.2340/00015555-2333. View

12.

Sathishkumar D, George R, Daniel D, Peter J . Clinical profile of childhood-onset psoriasis and prevalence of HLA-Cw6: a hospital-based study from India. Postgrad Med J. 2015; 91(1076):309-14. DOI: 10.1136/postgradmedj-2014-133188. View

13.

Gonzalez-Lara L, Batalla A, Coto E, Gomez J, Eiris N, Santos-Juanes J . The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. Arch Dermatol Res. 2014; 307(5):405-12. DOI: 10.1007/s00403-014-1533-z. View

14.

Talamonti M, Galluzzo M, Chimenti S, Costanzo A . HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up. J Am Acad Dermatol. 2016; 74(2):374-5. DOI: 10.1016/j.jaad.2015.08.055. View

15.

Mabuchi T, Ota T, Manabe Y, Ikoma N, Ozawa A, Terui T . HLA-C*12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol. 2014; 41(8):697-704. DOI: 10.1111/1346-8138.12569. View

16.

Callis Duffin K, Woodcock J, Krueger G . Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol Ther. 2010; 23(2):101-13. DOI: 10.1111/j.1529-8019.2010.01303.x. View

17.

Ruiz-Romeu E, Ferran M, Sagrista M, Gomez J, Gimenez-Arnau A, Herszenyi K . Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis. J Allergy Clin Immunol. 2016; 138(2):491-499.e6. DOI: 10.1016/j.jaci.2016.02.008. View

18.

Caldarola G, Sgambato A, Fanali C, Moretta G, Farina M, Lucchetti D . HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients. Pharmacogenet Genomics. 2016; 26(9):423-7. DOI: 10.1097/FPC.0000000000000233. View